Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
As Published on the  DePuy Hip Replacement  Website
DePuy hip replacement recalls forced Johnson & Johnson’s CEO to step down in April 2011. William Weldon, who has served as...
According to the Archives of Internal Medicine, the following compensations were made: * In 2007, $198 million paid out to...
In December 2009 DePuy pulled the devices off of the Australian market. It also announced a global recall in August 2010, ...
Transporting of microscopic metal parts into the body due to metal components rubbing against each other is one effect of ...
This may lead to metallosis, a type of blood poisoning, and genotoxicity, which is genetic damage.  Cancer and tumor may a...
“ Many people could have avoided considerable pain, suffering and diminished quality of life if the company had acted in a...
Upcoming SlideShare
Loading in …5
×

Issues of Johnson & Johnson Hip Recall System

747 views

Published on

http://www.depuyhipreplacementlawsuit.com/ - DePuy hip replacement recalls forced Johnson & Johnson’s CEO to step down in April 2011. William Weldon, who has served as top executive of Johnson & Johnson for nearly ten years, decided to step down in the midst of widespread consumer injury.

Published in: Business, Health & Medicine
  • Be the first to comment

  • Be the first to like this

Issues of Johnson & Johnson Hip Recall System

  1. 1. As Published on the DePuy Hip Replacement Website
  2. 2. DePuy hip replacement recalls forced Johnson & Johnson’s CEO to step down in April 2011. William Weldon, who has served as top executive of Johnson & Johnson for nearly ten years, decided to step down in the midst of widespread consumer injury. However, he will remain chairman of the company's board of directors. On a similar note, Johnson & Johnson, principal holding firm of the maker of the DePuy ASR hip replacement, is one of five artificial hip and knee manufacturers to cut back on payouts to surgeons in exchange for exclusive use of their products, Bloomberg News reports.
  3. 3. According to the Archives of Internal Medicine, the following compensations were made: * In 2007, $198 million paid out to 939 orthopedic surgeons. * In 2008, $119 million paid out to 568 surgeons, plus $109 million in royalty buyouts from Zimmer Holdings Inc.
  4. 4. In December 2009 DePuy pulled the devices off of the Australian market. It also announced a global recall in August 2010, approximately eight months after recalling them in Australia. Between 2008 and the time the recall was issued, the Food and Drug Administration (FDA) have received hundreds of complaints from ASR recipients, many of whom needed to have a second hip replacement surgery.
  5. 5. Transporting of microscopic metal parts into the body due to metal components rubbing against each other is one effect of design problems with metal-on-metal hip implant devices, like the DePuy. The metal particles shed from metal-on-metal hip replacement implants may increase the amount of some metals in the blood, such as chromium and cobalt.
  6. 6. This may lead to metallosis, a type of blood poisoning, and genotoxicity, which is genetic damage. Cancer and tumor may also be developed due to the presence of chromium and cobalt in the blood.
  7. 7. “ Many people could have avoided considerable pain, suffering and diminished quality of life if the company had acted in a responsible manner to known problems with these devices,” according to a legislative panel in Australia. Various complaining patients have been pursuing a hip replacement lawsuit against Johnson & Johnson.

×